Paris, November 24, 2021 - Orixha announces a €2 million financing round from Angels Santé, Erganeo and its industrial partners, InfiPlast, OEM Development and Activation. This round of financing will allow Orixha to develop its medical device Vent2Cool and to perform the first clinical trial of this liquid ventilation technology in cardiac arrest.
Created and supported by Erganeo, the start-up Orixha uses its proprietary liquid ventilation technology to offer an ultra-rapid induction solution for therapeutic hypothermia in Post Cardiac Arrest Syndrome.
"Vent2Cool induces cooling of vital organs in just a few minutes, not hours as it currently does. This rapidity allows to act on the origin of the after-effects by blocking the initial inflammatory and metabolic disorders. This should result in more patients surviving cardiac arrest" explains Professor Renaud Tissier, co-founder of Orixha.
Suat Topsu, President of Erganeo, says: "We are delighted to see that Vent2Cool is getting closer to the clinic and will help save lives. This disruptive innovation is the result of an academic collaboration between the University of Sherbrooke, INSERM and the Ecole Nationale Vétérinaire d'Alfort, orchestrated by Erganeo, which has also filed two patents and funded a maturation program to achieve preclinical proof of concept in 2018."
See the press release
Read more about Erganeo
